All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
On October 23, 2024, the U.S. Food and Drug Administration (FDA) granted fast track designation to HC-7366, a first-in-class small molecule activator of the general control nonderepressible 2 (GCN2) kinase, for the treatment of adult patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).1
HC-7366 is currently being investigated in combination with venetoclax plus azacitidine in an ongoing phase Ib trial (NCT06285890) to evaluate its recommended phase II dose, safety, tolerability, and preliminary efficacy in patients with R/R AML or myelodysplastic syndrome/AML with 10% to 19% blasts. Based on findings from the dose-escalation part, other combinations and monotherapy cohorts may be explored.1
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox